Nextera logo
  • About us
    • Management
    • Board of Directors
  • Technology
  • News & Events
  • Careers
  • Contact

Nextera US Patent granted

Jan 8, 2020 | News

The Nextera patent “Multivalent phage display systems and methods” was granted by the USPTO 8.1.2020.

This patent falls into an already strong portfolio of granted Nextera patents leveraging the commercial strategy for novel applications of the company’s drug discovery platform, NextCore.

← Previous Next →

Recent

  • Nextera’s NextCore technology applied to develop a unique peptide activator of the tissue injury Factor-VII activating protease (FSAP) in human plasma
  • Nextera’s unique NextCore display technology combined with state-of-the-art computational guidance efficiently generates low picomolar affinity TCR-Like antibodies
  • Nextera AS announces strategic collaboration with Zelluna Immunotherapy AS on development of optimized TCRs for redirected cancer immunotherapy
  • NextCore-generated state-of-the-art TCR-Like antibodies in celiac disease published in Science Immunology.
  • Nextera appoints Dr. Bent Jakobsen to the Board of Directors

Sort by

  • Meet us
  • News
  • Publications

Nextera AS

Oslo Innovation Centre
Gaustadalléen 21
, 0349 Oslo, Norway

  • Follow

Cookie Policy

Copyright 2020 Nextera AS
Design by Færd

Contact

Phone: +47 22 95 81 94
Mail: info@nextera.no

Navigation

About us
Management
Board of Directors
Technology
News & Events
Contact

Recent news

Nextera’s NextCore technology applied to develop a unique peptide activator of the tissue injury Factor-VII activating protease (FSAP) in human plasma

Oct 20, 2022

Factor-VII activating protease (FSAP) is a ubiquitously circulating zymogen plasma serine protease, which is rapidly activated upon tissue injury. FSAPs role in sepsis, trauma, stroke, and acute respiratory distress syndrome suggests that pro-FSAP activation is...

Nextera’s unique NextCore display technology combined with state-of-the-art computational guidance efficiently generates low picomolar affinity TCR-Like antibodies

Aug 26, 2022

The antibody engineering field is steadily evolving harnessing improvements in discovery engines and computational methods. Together with collaborators at OUS/UiO (Norway) and John Hopkins (US), we here describe a very powerful combination of the highly efficient...

Copyright 2020 Nextera AS
Design by Færd

Copyright 2020 Nextera AS
Design by Færd